 Drug Resistance, Multiple, Bacterial
"Drug Resistance, Multiple, Bacterial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
| Descriptor ID |
D024901
|
| MeSH Number(s) |
G06.099.225.812 G06.225.347.812 G07.690.773.984.269.347.812 G07.690.773.984.300.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Multiple, Bacterial".
- Biological Sciences [G]
- Microbiological Phenomena [G06]
- Bacterial Physiological Phenomena [G06.099]
- Drug Resistance, Bacterial [G06.099.225]
- Drug Resistance, Multiple, Bacterial [G06.099.225.812]
- Drug Resistance, Microbial [G06.225]
- Drug Resistance, Bacterial [G06.225.347]
- Drug Resistance, Multiple, Bacterial [G06.225.347.812]
- Physiological Phenomena [G07]
- Pharmacological and Toxicological Phenomena [G07.690]
- Pharmacological Phenomena [G07.690.773]
- Drug Resistance [G07.690.773.984]
- Drug Resistance, Microbial [G07.690.773.984.269]
- Drug Resistance, Bacterial [G07.690.773.984.269.347]
- Drug Resistance, Multiple, Bacterial [G07.690.773.984.269.347.812]
- Drug Resistance, Multiple [G07.690.773.984.300]
- Drug Resistance, Multiple, Bacterial [G07.690.773.984.300.500]
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Multiple, Bacterial".
This graph shows the total number of publications written about "Drug Resistance, Multiple, Bacterial" by people in this website by year, and whether "Drug Resistance, Multiple, Bacterial" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 3 | 1 | 4 | | 2006 | 2 | 0 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 5 | 5 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 4 | 1 | 5 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 1 | 2 | | 2019 | 5 | 1 | 6 | | 2020 | 1 | 0 | 1 | | 2021 | 4 | 4 | 8 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 3 | 3 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Multiple, Bacterial" by people in Profiles.
-
Ray S, Flemming LK, Scudder CJ, Ly MA, Porterfield HS, Smith RD, Clark AE, Johnson JK, Das S. Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing. Microbiol Spectr. 2025 Apr; 13(4):e0252724.
-
Harris SL, Dutta S, Liu N, Wollenberg T, Wang X. Extended structure-activity relationship studies of the [1,2,5]oxadiazolo[3,4-b]pyrazine-containing colistin adjuvants. Bioorg Med Chem Lett. 2025 Jan 01; 115:130008.
-
Bullen NP, Johnson CN, Andersen SE, Arya G, Marotta SR, Lee YJ, Weigele PR, Whitney JC, Duerkop BA. An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense. Nat Commun. 2024 Aug 13; 15(1):6955.
-
Mueller SW, Molina KC, Blass B, Gibson C, Kohler AD, Krsak M, Wiktor AJ. Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa. J Burn Care Res. 2024 05 06; 45(3):808-810.
-
Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024 Jan 11; 12(1):e0235123.
-
Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol Spectr. 2022 10 26; 10(5):e0047922.
-
Otoupal PB, Eller KA, Erickson KE, Campos J, Aunins TR, Chatterjee A. Potentiating antibiotic efficacy via perturbation of non-essential gene expression. Commun Biol. 2021 11 05; 4(1):1267.
-
Dombach JL, Quintana JLJ, Detweiler CS. Staphylococcal Bacterial Persister Cells, Biofilms, and Intracellular Infection Are Disrupted by JD1, a Membrane-Damaging Small Molecule. mBio. 2021 10 26; 12(5):e0180121.
-
Jonas D, Reuter S, Klassen S, Weber S, Buck M, Giani T, Rossolini GM, Grundmann H. Evaluation of the BD Phoenix CPO detect panel for prediction of Ambler class carbapenemases. Sci Rep. 2021 06 23; 11(1):13150.
-
McCollum CR, Bertram JR, Nagpal P, Chatterjee A. Photoactivated Indium Phosphide Quantum Dots Treat Multidrug-Resistant Bacterial Abscesses In Vivo. ACS Appl Mater Interfaces. 2021 Jul 07; 13(26):30404-30419.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|